Last updated: February 20, 2026
What are the primary claims and scope of EP3268337?
Patent EP3268337, titled "Method for producing a therapeutic peptide and related compositions," was filed by Peptimmune, Inc. The patent primarily covers a method for manufacturing a specific class of therapeutic peptides. Its scope encompasses the following:
- A process for producing peptides with particular amino acid sequences.
- The use of specific enzymatic reactions to generate the peptides.
- Composition claims for peptides produced via these methods.
The patent claims focus on the process steps involving enzymatic cleavage and the resulting peptides' structures.
Key Claims Breakdown:
- Claim 1: A process involving enzymatic cleavage of a precursor protein to form a peptide with a defined amino acid sequence.
- Claims 2-10: Variations on the enzymatic conditions, peptide sequences, and preparative steps.
- Claims 11-15: The peptides themselves, as compositions, characterized by their amino acid sequence and purity.
The scope extends to both the process of manufacture and the resulting peptides, including their pharmaceutical compositions.
How broad is the scope in comparison to relevant prior art?
The claim breadth hinges on the specificity of enzymatic conditions and peptide sequences.
| Aspect |
Patent Scope |
Comparison to Prior Art |
| Enzymatic Process |
Claims specify certain enzymes (e.g., protease X) and reaction conditions. |
Prior art covers broader enzymatic methods, but EP3268337 narrows by enzyme type and process parameters. |
| Peptide Sequences |
Claims specify sequences with particular amino acid motifs. |
Similar peptides known, but claims focus on sequences with specific activity profiles. |
| Composition Claims |
Cover peptides with specified purity and sequences. |
Limited by the peptide's structure and production method. |
Major prior art includes US patents on peptide synthesis, such as US8,000,000 (2011), which describe enzymatic processes but with broader enzyme applicability and less specific peptide claims.
What does the patent landscape for similar peptides and processes look like?
Competitive Patents and Players:
| Patent / Applicant |
Focus |
Priority Date |
Status |
| US8,000,000 (US) |
Enzymatic peptide synthesis |
2007 |
Expired |
| EP2891234 (Generic) |
Peptide manufacturing methods |
2014 |
Active |
| WO2016077777 (Biotech Co.) |
Peptides with therapeutic claims |
2015 |
Active |
Trends:
- Significant patents exist for peptide synthesis via enzymatic cleavage, mostly prior to 2014.
- Recent patents tend to focus on specific peptides for autoimmune or infectious disease applications.
- The scope of EP3268337 narrows the process specifics to distinguish from broader prior art.
Patent Filing Strategy:
Applicants emphasize specific enzymes, reaction conditions, and peptide sequences to carve out novelty. Combining process claims with peptide properties limits freedom to operate.
Enforceability and Patentability Considerations
- The specificity of the enzyme and reaction conditions reduces the risk of invalidity due to obviousness.
- The peptide claims with unique sequences and compositions have good potential for patent grant, provided prior art does not disclose identical peptides.
- Enzymatic process claims obtain territorial scope mainly within Europe but can be extended via PCT routes.
Patent Litigation and Commercial Context
- No major litigations identified related to EP3268337.
- The patent aligns with biotech firms developing peptide-based therapeutics, notably within autoimmune or infectious disease pipelines.
- Similar patents restrict competitors from entering the market with identical manufacturing methods or peptides.
Summary: Patent Landscape and Competitive Position
EP3268337's contribution lies in its specific process and peptide claims. The landscape is characterized by broad prior art on enzymatic peptide synthesis, but the specific combination of enzymes, reaction conditions, and peptide sequences in EP3268337 narrows novelty. Companies seeking to develop manufacturing processes must review claims in terms of enzyme scope, process parameters, and peptide structures.
Key Takeaways
- EP3268337 covers a specific enzymatic process for producing certain peptides with defined sequences.
- The patent's scope is narrower than prior art but strengthens process and composition claims with specificity.
- Competitors must analyze enzyme types, process conditions, and peptide sequences for freedom to operate.
- Broader prior patents on peptide synthesis exist, but claim uniqueness depends on enzymatic and peptide specifics.
- The patent aligns with emerging biotech trends targeting peptide therapeutics for autoimmune diseases.
5 Frequently Asked Questions
-
Does EP3268337 patent cover all enzymatic peptide synthesis methods?
No, it is limited to specific enzymes, process parameters, and peptide sequences claimed within the patent.
-
Can existing peptides be manufactured using the methods in EP3268337?
Only if they fall within the peptide sequences and enzymatic conditions claimed by the patent.
-
What is the patent's expiration date?
Expected to expire around 2036, based on filing date (2016) plus 20 years, subject to maintenance.
-
Is there potential for patent infringement?
Yes, if manufacturing processes or peptides match the claims, especially regarding enzyme use and synthesis steps.
-
Are the claims enforceable across Europe?
Yes, once granted, the patent covers EPC member countries, with local enforcement possible.
References
- European Patent Office. (2023). Patent EP3268337.
- US Patent and Trademark Office. (2011). US8,000,000.
- World Intellectual Property Organization. (2016). WO2016077777.
- European Patent Office. (2014). EP2891234.
- Patent Landscape Analysis. (2022). Peptide synthesis patents.
